Sofie Meulewaeter

ORCID: 0000-0003-4638-4831
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Immunotherapy and Immune Responses
  • RNA Interference and Gene Delivery
  • Immune Cell Function and Interaction
  • Monoclonal and Polyclonal Antibodies Research
  • Protein purification and stability
  • Orthopedic Infections and Treatments
  • Animal Virus Infections Studies
  • Cancer Immunotherapy and Biomarkers
  • Brake Systems and Friction Analysis
  • Mathematical Biology Tumor Growth
  • Nanoparticle-Based Drug Delivery
  • vaccines and immunoinformatics approaches

Ghent University
2023-2024

Cancer Research Institute Ghent
2023-2024

Ghent University Hospital
2020-2024

Although various types of mRNA-based vaccines have been explored, the optimal conditions for induction both humoral and cellular immunity remain rather unknown. In this study, mRNA nucleoside-modified in lipoplexes (LPXs) or lipid nanoparticles (LNPs) were evaluated after administration mice through different routes, assessing delivery, tolerability immunogenicity. addition, we investigated whether could benefit from inclusion adjuvant alpha-galactosylceramide (αGC), an invariant Natural...

10.1016/j.jconrel.2024.04.052 article EN cc-by Journal of Controlled Release 2024-05-04

Rationale: Although promising responses are obtained in patients treated with immune checkpoint inhibitors targeting programmed death ligand 1 (PD-L1) and its receptor death-1 (PD-1), only a fraction of benefits from this immunotherapy.Cancer vaccination may be an effective approach to improve the response anti-PD-L1/PD-1 therapy.However, there is lack research on dynamics PD-L1 expression cancer vaccination.Methods: We performed non-invasive whole-body imaging visualize at different...

10.7150/thno.85106 article EN cc-by Theranostics 2023-01-01

Abstract Background: Multiple myeloma (MM) is a plasma cell cancer for which immunotherapy holds the promise of durable control. To date, vaccines mainly focused on tumor-associated antigens with survivin eliciting protective T-cell responses in both preclinical and clinical studies. Given success mRNA medicine, we developed Galsomes, lipid nanoparticles containing α-galactosyl ceramide to activate CD8+ T cells invariant natural killer (iNK) cells, potential anti-MM effectors. Materials...

10.1158/1538-7445.am2024-4110 article EN Cancer Research 2024-03-22

The article presents the use of Gompertz model to analyze growth profile tumors and evaluate treatment effects. convenience curve is its slow initial growth, followed by an inflection point (not necessarily symmetric between lower maximum volume size) a stabilization until it reaches value. Given double exponential present in estimation value needed proceed with linearization. In general, for ethical reasons, animal experiments are stopped early stages. Before they reach saturation, most...

10.2139/ssrn.4364283 article EN 2023-01-01
Coming Soon ...